Our vision is to be the trusted engine for regenerative medicine – advancing restorative medicines through world-class technology and deep therapeutic partnerships.
We are a therapeutics company built on partnership and platform value creation with an adaptable model to ensure next generation cell therapies get to patients sooner.
— Licensing, or co-development. Pick the model that fits your needs.
Licensing opportunities.
Co-development partnership.
Access best-in-class microtissue assets with a clear path to clinic.
Work with the best scientists across biophysics, engineering and stem cell biology.
We have developed C-stem™, a GMP-compliant technology platform designed to solve the scalability and quality issues facing the efficient mass production of next-generation cell therapies.
It is the world’s first capsule technology platform that protects stem cells within biomimetic capsules, enabling industrial-scale production without compromising on cell quality or genomic integrity.
First bioreactor-based, closed system for end-to-end culture (GMP-compliant).
Biomimetic protection supports exponential amplification and differentiation while minimizing shear stress in a single workflow.
Reduced operator intervention to lower variability and improve process robustness
Power your pipeline with C-Stem™ to deliver high-quality, cost-effective cell therapies for millions of patients.
Learn more on C-Stem™ here →Traditional 2D culture (petri dishes) is difficult to scale. C-Stem™ allows for exponential expansion in 3D, which is more efficient for industrial manufacturing.
Because the cells are grown as 3D microtissues, they are “ready-to-transplant,” which can lead to better engraftment and reduced time-to-effect compared to single-cell suspensions.
The platform is an automated, GMP-compliant closed system (ISO 6 compatible), reducing the risk of variability and contamination.
— A platform that travels.
From iPSC-derived neurons to donor-derived MSCs.
01
02
03
04
05
06
08
09
10We have a history of scientific collaborations, co-development and licensing agreements.
We have proven results in pre-clinical models, particularly in Parkinson’s disease and Liver.
Link to pipeline page →